Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Open
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Eligible for screening study DCP 001
NCT#04457596